30th Mar 2015 08:50
LONDON (Alliance News) - Hutchison China MediTech Ltd on Monday said the first proof-of-concept trial conducted on its fruquintinib metastatic colorectal cancer treatment has met its primary efficacy target.
The top-line results from the study, conducted through its Hutchison MediPharma Ltd drug research and development subsidiary, showed it met its initial efficacy endpoint of progression free survival, or the length of time during and after a disease that a patient lives but the disease does not get worse.
It said assessment of the secondary endpoint targets is ongoing, with all appearing in line with expectations at the six-month data cut-off point in February.
Shares in Hutchison China were up 1.5% to 1,309.7 pence on Monday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed